Paul B. Manning - 30 Jun 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Director
Issuer ticker: CADL
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2026, 16:21:13 UTC
Prior SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Schoch, as Attorney-In-Fact for Paul B. Manning

Key filing fact

Paul B. Manning filed Form 4 for Candel Therapeutics, Inc. (CADL) on 01 Jul 2026.

Key facts

This page summarizes Paul B. Manning's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Jul 2026, 16:21.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001494695 Primary reporting owner

Relationship: Director
Address: C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM
Signature: /s/ Charles Schoch, as Attorney-In-Fact for Paul B. Manning
Signature date: 01 Jul 2026

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.